 |
인쇄하기
취소
|
New drug policy perplexes GSK
As the government decided to exclude Tykerb (lapatinib) from the list of national health insurance last month, GlaxoSmithKline is in dilemma to launch the product, saying it would limit Korean patients' access to newly-developed drugs.
The Health Insurance Review & Assessment Service said Tykerb's price over efficacy cannot be found, when compared to Herceptin, another breast cancer drug.
...
The Health Insurance Review & Assessment Service said Tykerb's price over efficacy cannot be found, when compared to Herceptin, another breast cancer drug.
...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.